Formulated nano-liposomes for reversal of cisplatin resistance in NSCLC with nucleus-targeting peptide
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Formulated nano-liposomes for reversal of cisplatin resistance in NSCLC with nucleus-targeting peptide
Authors
Keywords
-
Journal
Nano Research
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-06
DOI
10.1007/s12274-023-6273-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The use of nanoparticles for targeted drug delivery in non-small cell lung cancer
- (2023) Jessica E. Holder et al. Frontiers in Oncology
- Cell membrane coated-nanoparticles for cancer immunotherapy
- (2022) Yingping Zeng et al. Acta Pharmaceutica Sinica B
- A nucleus-targeting peptide antagonist towards EZH2 displays therapeutic efficacy for lung cancer
- (2022) Mei Jiang et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Engineering cancer cell membrane-camouflaged metal complex for efficient targeting therapy of breast cancer
- (2022) Xiaoying Li et al. JOURNAL OF NANOBIOTECHNOLOGY
- Non‐small cell lung cancer in China
- (2022) Peixin Chen et al. Cancer Communications
- Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells
- (2021) Daolu Yang et al. Molecular Therapy-Nucleic Acids
- Prognostic significance of epigenetic regulatory gene expression in patients with non-small-cell lung cancer
- (2021) Zegui Tu et al. Aging-US
- Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair–inhibiting (HYDRI) nanomedicine
- (2021) Jing Chen et al. Science Advances
- Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth
- (2021) Jie Zhang et al. CANCER LETTERS
- Cell membrane–camouflaged liposomes for tumor cell–selective glycans engineering and imaging in vivo
- (2021) Zhengwei Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cisplatin resistance of NSCLC cells involves upregulation of visfatin through activation of its transcription and stabilization of mRNA
- (2021) Zihao Lu et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Histone modifications and their role in epigenetics of cancer
- (2021) Sumera Zaib et al. CURRENT MEDICINAL CHEMISTRY
- CBX2 and EZH2 cooperatively promote the growth and metastasis of lung adenocarcinoma
- (2021) Fei-Fei Hu et al. Molecular Therapy-Nucleic Acids
- A positive feedback loop formed by NGFR and FOXP3 contributes to the resistance of non-small cell lung cancer to icotinib
- (2020) Jun Huang et al. Translational Cancer Research
- Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression
- (2020) Xueyan Zang et al. Cell Death & Disease
- Association of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin Resistance
- (2020) Milad Ashrafizadeh et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A novel PPARɣ ligand, PPZ023, overcomes radioresistance via ER stress and cell death in human non-small-cell lung cancer cells
- (2020) Tae Woo Kim et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Advances in Oligonucleotide Aptamers for NSCLC Targeting
- (2020) Deborah Rotoli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Epigenetic therapy for ovarian cancer: promise and progress
- (2019) Sara Moufarrij et al. Clinical Epigenetics
- Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
- (2019) Edward B. Garon et al. JOURNAL OF CLINICAL ONCOLOGY
- LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC
- (2019) Xinyin Liu et al. Molecular Therapy-Nucleic Acids
- New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
- (2019) Shang-Hung Chen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Aberrant N-cadherin expression in cancer
- (2019) Zhan-Qi Cao et al. BIOMEDICINE & PHARMACOTHERAPY
- pH-Sensitive N,N-Dimethylalkane-1-amine N-Oxides in DNA Delivery: From Structure to Transfection Efficiency
- (2019) Gilda Liskayová et al. LANGMUIR
- EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression
- (2019) Dongwei Dou et al. OncoTargets and Therapy
- Frontline immunotherapy for NSCLC: alone or not alone?
- (2018) Cesare Gridelli et al. Nature Reviews Clinical Oncology
- The efficiency of lipid nanoparticles with an original cationic lipid as a siRNA delivery system for macrophages and dendritic cells
- (2018) Yasunori Uemura et al. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
- (2018) Ugo Testa et al. Cancers
- P2-001The functional role of NGFR in regulating chemosensitivity in nasopharyngeal carcinoma
- (2018) Wei Gao et al. ANNALS OF ONCOLOGY
- A central role for cadherin signaling in cancer
- (2017) Antonis Kourtidis et al. EXPERIMENTAL CELL RESEARCH
- Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
- (2017) Meng Zhang et al. Cancer Biology & Medicine
- Liposomes Coated with Isolated Macrophage Membrane Can Target Lung Metastasis of Breast Cancer
- (2016) Haiqiang Cao et al. ACS Nano
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- Cisplatin resistance and opportunities for precision medicine
- (2016) Lauren Amable PHARMACOLOGICAL RESEARCH
- Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis
- (2016) Xinhua Wang et al. Scientific Reports
- siRNA Silencing EZH2 Reverses Cisplatin-resistance of Human Non-small Cell Lung and Gastric Cancer Cells
- (2015) Wen Zhou et al. Asian Pacific Journal of Cancer Prevention
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy
- (2014) Chunhua Xu et al. LUNG CANCER
- Systems biology of cisplatin resistance: past, present and future
- (2014) L Galluzzi et al. Cell Death & Disease
- Nanomedicine therapeutic approaches to overcome cancer drug resistance
- (2013) Janet L. Markman et al. ADVANCED DRUG DELIVERY REVIEWS
- Prognostic Significance of Twist and N-Cadherin Expression in NSCLC
- (2013) Linping Hui et al. PLoS One
- Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
- (2012) Che-Ming Jack Hu et al. BIOCHEMICAL PHARMACOLOGY
- Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)
- (2012) Corey J. Langer et al. CANCER TREATMENT REVIEWS
- Cancer Epigenetics: From Mechanism to Therapy
- (2012) Mark A. Dawson et al. CELL
- The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications
- (2012) Mark P Chao et al. CURRENT OPINION IN IMMUNOLOGY
- Genetic heterogeneity and cancer drug resistance
- (2012) Nicholas C Turner et al. LANCET ONCOLOGY
- Histone methylation: a dynamic mark in health, disease and inheritance
- (2012) Eric L. Greer et al. NATURE REVIEWS GENETICS
- Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer
- (2011) Huqun et al. CANCER
- Vimentin in cancer and its potential as a molecular target for cancer therapy
- (2011) Arun Satelli et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Cell signaling molecules as drug targets in lung cancer: an overview
- (2011) Tapan K Mukherjee et al. CURRENT OPINION IN PULMONARY MEDICINE
- Ovarian Cancer Stem Cell-Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2
- (2011) S. Rizzo et al. MOLECULAR CANCER THERAPEUTICS
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo
- (2010) Sha Hu et al. CANCER BIOLOGY & THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now